CY1112864T1 - Καινουργιες μορφες μεθυλικου εστερα cddo - Google Patents

Καινουργιες μορφες μεθυλικου εστερα cddo

Info

Publication number
CY1112864T1
CY1112864T1 CY20121100542T CY121100542T CY1112864T1 CY 1112864 T1 CY1112864 T1 CY 1112864T1 CY 20121100542 T CY20121100542 T CY 20121100542T CY 121100542 T CY121100542 T CY 121100542T CY 1112864 T1 CY1112864 T1 CY 1112864T1
Authority
CY
Cyprus
Prior art keywords
cddo
crystalline
new models
methyl ester
vitreous
Prior art date
Application number
CY20121100542T
Other languages
English (en)
Inventor
John Walling
Stephan D Parent
David T Jonaitis
Robert M Kral
Original Assignee
Reata Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reata Pharmaceuticals, Inc. filed Critical Reata Pharmaceuticals, Inc.
Publication of CY1112864T1 publication Critical patent/CY1112864T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Glass Compositions (AREA)

Abstract

Μία ένωση τριτερπενοειδούς (triterpenoid), methyl 2-cyano-3,12-dioxoleana- 1,9(1 1)-dien-28-oate (μεθυλικός εστέρας CDDO), έχει μία μη κρυσταλλική, υαλώδη στερεά μορφή και μία μη ένυδρη κρυσταλλική μορφή που μπορούν να παρασκευαστούν, για παράδειγμα, από ένα κεκορεσμένο διάλυμα μεθανόλης (methanol). Η υαλώδης μορφή εμφανίζει μία αυξημένη βιολογική διαθεσιμότητα έναντι της μη ένυδρης κρυσταλλικής μορφής. Κάθε μορφή μεθυλικού εστέρα CDDΟ είναι ένας ανώτερος υποψήφιος για χρήση, τυπικά σε μορφή στερεάς δοσολογίας, για την θεραπεία μιας ποικιλίας καταστάσεων ασθενείας, που σχετίζονται εν γένει με φλεγμονή.
CY20121100542T 2007-08-15 2012-06-13 Καινουργιες μορφες μεθυλικου εστερα cddo CY1112864T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95593907P 2007-08-15 2007-08-15
EP08795303A EP2187741B1 (en) 2007-08-15 2008-08-14 Novel forms of cddo methyl ester

Publications (1)

Publication Number Publication Date
CY1112864T1 true CY1112864T1 (el) 2016-04-13

Family

ID=40351005

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20121100542T CY1112864T1 (el) 2007-08-15 2012-06-13 Καινουργιες μορφες μεθυλικου εστερα cddo
CY20161101205T CY1118329T1 (el) 2007-08-15 2016-11-23 Καινουργιες μορφες μεθυλικου εστερα cddo

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20161101205T CY1118329T1 (el) 2007-08-15 2016-11-23 Καινουργιες μορφες μεθυλικου εστερα cddo

Country Status (29)

Country Link
US (3) US8088824B2 (el)
EP (2) EP2187741B1 (el)
JP (4) JP5005812B2 (el)
KR (2) KR101544766B1 (el)
CN (2) CN103254267B (el)
AR (2) AR073155A1 (el)
AT (1) ATE549035T1 (el)
AU (1) AU2008287388B2 (el)
BR (1) BRPI0815540A8 (el)
CA (2) CA2696330C (el)
CL (1) CL2008002417A1 (el)
CY (2) CY1112864T1 (el)
DK (2) DK2450057T3 (el)
EA (2) EA023550B1 (el)
ES (2) ES2382571T3 (el)
HK (1) HK1143537A1 (el)
HR (2) HRP20120350T1 (el)
HU (1) HUE031866T2 (el)
IL (2) IL203824A (el)
LT (1) LT2450057T (el)
MX (1) MX2010001628A (el)
NZ (1) NZ583269A (el)
PL (2) PL2187741T3 (el)
PT (2) PT2450057T (el)
SG (2) SG10201504650VA (el)
SI (2) SI2187741T1 (el)
TW (2) TWI419899B (el)
WO (1) WO2009023232A1 (el)
ZA (1) ZA201001066B (el)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326507B1 (en) * 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US7435755B2 (en) 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
EP1465615B1 (en) 2002-01-15 2012-08-01 Trustees of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
US8921340B2 (en) 2006-11-17 2014-12-30 Trustees Of Dartmouth College Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions
JP2010510243A (ja) 2006-11-17 2010-04-02 トラスティーズ オブ ダートマス カレッジ 三環系−ビス−エノン（ｔｂｅ）の合成および生物学的活性
WO2008064132A2 (en) 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
US8088824B2 (en) * 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
RS58486B1 (sr) * 2008-01-11 2019-04-30 Reata Pharmaceuticals Inc Sintetički triterpenoidi i metode njihove upotrebe u tretmanu bolesti
BRPI0911422B8 (pt) 2008-04-18 2021-05-25 Reata Pharmaceuticals Inc compostos moduladores inflamatórios antioxidantes, composição farmacêutica e usos dos mesmos
PL2276493T3 (pl) * 2008-04-18 2019-05-31 Reata Pharmaceuticals Inc Antyoksydacyjne modulatory stanu zapalnego: pochodne kwasu oleanolowego z amino- i innymi modyfikacjami przy C-17
CN102066397B (zh) 2008-04-18 2013-09-11 里亚塔医药公司 包含抗炎症药效团的化合物以及使用方法
CN102164941B (zh) 2008-04-18 2015-05-27 里亚塔医药公司 抗氧化剂炎症调节剂:具有饱和c环的齐墩果酸衍生物
TW201004627A (en) 2008-04-18 2010-02-01 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: novel derivatives of oleanolic acid
AU2009274037B2 (en) 2008-07-22 2015-07-09 Trustees Of Dartmouth College Monocyclic cyanoenones and methods of use thereof
KR101483203B1 (ko) * 2009-02-13 2015-01-15 리아타 파마슈티컬즈, 아이엔씨. 무정형 ｃｄｄｏ-ｍｅ를 포함하는, 지연 방출형 경구 투여 조성물
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
ME03713B (me) 2010-04-12 2021-01-20 Reata Pharmaceuticals Inc Bardoksolon meтil za lečenje gojaznosтi
PL2651902T3 (pl) 2010-12-17 2018-04-30 Reata Pharmaceuticals, Inc. Pirazolilowe i pirymidynylowe tricykliczne enony jako modulatory zapalenia o działaniu przeciwutleniającym
UY33946A (es) 2011-03-11 2012-08-31 Reata Pharmaceuticals Inc Derivados de c4-monometil triterpenoides y sus métodos de uso
CN103156861B (zh) * 2011-12-08 2015-11-25 陈丽梅 齐敦果酸衍生物及其可药用盐在治疗糖尿病眼病中的应用
PT2841445T (pt) 2012-04-27 2017-09-01 Reata Pharmaceuticals Inc Derivados de 2,2-difluoropropionamida de metil bardoxolona, formas polimorfas e métodos de uso dos mesmos
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
US8981144B2 (en) 2012-05-08 2015-03-17 Trustees Of Dartmouth College Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof
WO2013188818A1 (en) 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
CA2884400A1 (en) * 2012-09-10 2014-03-13 Abbvie Inc. Glycyrrhetinic acid derivatives and methods of use thereof
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
PE20150627A1 (es) 2012-09-10 2015-06-04 Reata Pharmaceuticals Inc Derivados de c17-alcandiilo y alquendiilo del acido oleanolico y sus metodos de uso
JP5972986B2 (ja) 2012-09-28 2016-08-17 アプライド ファーマシューティカル サイエンス インコーポレイテッド Ｃｄｄｏエチルエステルの多形体及びその用途
CN102887936A (zh) * 2012-10-24 2013-01-23 苏州晶云药物科技有限公司 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯晶型
CN102875634B (zh) * 2012-10-24 2014-08-20 苏州晶云药物科技有限公司 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯的几种晶型
EP2977381B1 (en) 2013-03-19 2018-09-26 Daiichi Sankyo Company, Limited Terpenoid derivative
TW201936625A (zh) 2013-04-24 2019-09-16 美商艾伯維有限公司 甲基巴多索龍之2,2-二氟丙醯胺衍生物、其多晶形及其使用方法
SG10201906113RA (en) * 2013-08-23 2019-08-27 Reata Pharmaceuticals Inc Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
WO2016033132A1 (en) 2014-08-26 2016-03-03 Trustees Of Dartmouth College Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole
US10189791B2 (en) 2014-08-26 2019-01-29 Trustees Of Dartmouth College Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole
CN106661080A (zh) 2014-09-10 2017-05-10 第三共株式会社 用于治疗和预防眼科疾病的缓释药物组合物
WO2016089648A1 (en) 2014-12-01 2016-06-09 Vtv Therapeutics Llc Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof
US11591302B2 (en) 2014-12-19 2023-02-28 Geistlich Pharm A Ag Processes for preparing oxathiazin-like compounds
HRP20220313T1 (hr) 2014-12-19 2022-05-13 Geistlich Pharma Ag Procesi za pripremu spojeva sličnih oksatiazinu
JP6748652B2 (ja) 2015-02-12 2020-09-02 リアタ ファーマシューティカルズ インコーポレイテッド 抗酸化性炎症調節剤としてのイミダゾリル三環式エノン
PL3317281T3 (pl) * 2015-07-02 2020-11-02 Acerta Pharma B.V. Postacie stałe i formulacje (s)-4-(8-amino-3-(1-(but-2-ynoilo)pirolidyn-2-ylo)imidazo[1,5-a]-pirazyn-1-ylo)-n-(pirydyn-2-ylo)benzamidu
EA201890767A1 (ru) 2015-09-23 2019-09-30 Рита Фармасьютикалз, Инк. C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений
US10953020B2 (en) 2016-11-08 2021-03-23 Reata Pharmaceuticals, Inc. Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
WO2019014412A1 (en) 2017-07-13 2019-01-17 Pliva Hrvatska D.O.O. NOVEL CRYSTALLINE POLYMORPHIC FORMS OF METHYL BARDOXOLONE
CN112654610A (zh) 2018-06-15 2021-04-13 里亚塔医药公司 用于抑制IL-17和RORγ的吡唑和咪唑化合物
TW202038918A (zh) 2018-11-27 2020-11-01 日商協和麒麟股份有限公司 醫藥組合物
US20230255982A1 (en) 2020-05-09 2023-08-17 Reata Pharmaceuticals Holdings, LLC Methods of treating covid-19 using bardoxolone methyl or analogs thereof
EP4259155A1 (en) 2020-12-11 2023-10-18 Reata Pharmaceuticals Holdings, LLC Synthetic triterpenoids for use in therapy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07121911B2 (ja) * 1986-03-26 1995-12-25 クミアイ化学工業株式会社 ４（１ｈ）−ピリジノン誘導体および農園芸用殺菌剤
JPH01273020A (ja) * 1988-04-26 1989-10-31 Toray Ind Inc 有機非線形光学材料
US5064823A (en) * 1988-08-24 1991-11-12 Research Triangle Institute Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers
JP2876144B2 (ja) * 1990-03-23 1999-03-31 東洋フアルマー株式会社 ３―フェニルクマリン―７―イルオキシ酢酸誘導体とその製法及び用途
GB9622173D0 (en) * 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
US20050276836A1 (en) * 1997-06-11 2005-12-15 Michelle Wilson Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US6890946B2 (en) * 1999-12-23 2005-05-10 Indiana University Research And Technology Corporation Use of parthenolide to inhibit cancer
US7435755B2 (en) * 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
AU2002243246A1 (en) * 2000-11-28 2002-06-24 Board Of Regents, The University Of Texas System Cddo-compounds and combination therapies thereof
CA2485565A1 (en) * 2002-05-13 2004-08-05 Trustees Of Dartmouth College Inhibitors and methods of use thereof
JP3618341B2 (ja) * 2003-04-15 2005-02-09 山之内製薬株式会社 臭化物及びその結晶
FR2861299B1 (fr) * 2003-10-28 2006-01-27 Pf Medicament Compositions pharmaceutiques a base de derives d'idasoxan sous formes polymorphes
WO2005057275A1 (ja) 2003-12-08 2005-06-23 Sony Corporation 液晶表示装置およびバックライト調整方法
US20060167097A1 (en) * 2004-04-16 2006-07-27 Cheppail Ramachandran Compositions and uses of Amooranin compounds
WO2006127926A2 (en) * 2005-05-23 2006-11-30 Novartis Ag Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
DE102005041613A1 (de) 2005-09-01 2007-03-08 Ergonex Pharma Gmbh Pharmazeutische Zusammensetzungen zur Behandlung von Karzinoid-Syndrom
NZ569078A (en) 2005-12-12 2012-01-12 Mosamedix Bv Annexin derivatives suitable for pretargeting in therapy and diagnosis
US8088824B2 (en) * 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester

Also Published As

Publication number Publication date
TWI486357B (zh) 2015-06-01
ES2602978T3 (es) 2017-02-23
IL203824A (en) 2017-04-30
US20090048204A1 (en) 2009-02-19
CA2696330C (en) 2015-03-24
EP2450057A1 (en) 2012-05-09
WO2009023232A1 (en) 2009-02-19
CA2871864A1 (en) 2009-02-19
JP2010536754A (ja) 2010-12-02
ZA201001066B (en) 2010-10-27
CY1118329T1 (el) 2017-06-28
EA023550B1 (ru) 2016-06-30
TW200916476A (en) 2009-04-16
KR20140024063A (ko) 2014-02-27
BRPI0815540A2 (pt) 2014-09-30
JP5005812B2 (ja) 2012-08-22
ATE549035T1 (de) 2012-03-15
CA2696330A1 (en) 2009-02-19
KR20100056488A (ko) 2010-05-27
CA2871864C (en) 2016-05-17
AR119704A2 (es) 2022-01-05
PT2187741E (pt) 2012-06-21
EP2187741A1 (en) 2010-05-26
DK2450057T3 (en) 2016-12-19
AU2008287388A1 (en) 2009-02-19
AR073155A1 (es) 2010-10-20
AU2008287388B2 (en) 2014-11-06
BRPI0815540A8 (pt) 2023-04-11
KR101544766B1 (ko) 2015-08-17
EA018704B1 (ru) 2013-10-30
PL2450057T3 (pl) 2017-02-28
JP2018009001A (ja) 2018-01-18
CN103254267B (zh) 2016-03-16
US8309601B2 (en) 2012-11-13
CN101820758B (zh) 2013-03-06
JP2012188438A (ja) 2012-10-04
CN103254267A (zh) 2013-08-21
SI2187741T1 (sl) 2012-07-31
US8088824B2 (en) 2012-01-03
SG177905A1 (en) 2012-02-28
EP2187741B1 (en) 2012-03-14
US20120071684A1 (en) 2012-03-22
TWI419899B (zh) 2013-12-21
EA201070149A1 (ru) 2010-08-30
ES2382571T3 (es) 2012-06-11
HUE031866T2 (en) 2017-08-28
DK2187741T3 (da) 2012-04-16
MX2010001628A (es) 2010-06-02
CN101820758A (zh) 2010-09-01
EA201370109A1 (ru) 2014-01-30
CL2008002417A1 (es) 2009-03-27
HRP20161503T1 (hr) 2017-01-13
SI2450057T1 (sl) 2017-01-31
SG10201504650VA (en) 2015-07-30
HRP20120350T1 (hr) 2012-05-31
US20120330050A1 (en) 2012-12-27
EP2450057B1 (en) 2016-09-28
PL2187741T3 (pl) 2012-08-31
PT2450057T (pt) 2016-12-15
TW201402597A (zh) 2014-01-16
IL251419A0 (en) 2017-05-29
EP2187741A4 (en) 2010-08-25
JP2015164939A (ja) 2015-09-17
HK1143537A1 (en) 2011-01-07
NZ583269A (en) 2012-03-30
KR101481764B1 (ko) 2015-01-13
LT2450057T (lt) 2016-12-27
US8633243B2 (en) 2014-01-21

Similar Documents

Publication Publication Date Title
CY1118329T1 (el) Καινουργιες μορφες μεθυλικου εστερα cddo
CL2022001271A1 (es) Agonista del receptor glp-1 y uso de este
CY1121899T1 (el) Βοριουχα μικρομορια ως αντιφλεγμονωδεις παραγοντες
ECSP088774A (es) Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmacéuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricación.
CL2011002849A1 (es) Composicion anti-inflamatoria que comprende microorganismos sometidos a tratamiento a por lo menos 71,5 grados celsius durante por lo menos 1 segundo; uso de una composicion para tratar o prevenir padecimientos inflamatorios; metodos para proporcionar los microorganismos.
UY30639A1 (es) Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
CL2008001879A1 (es) Compuestos derivados de isaxolinas-naftalen-carboamida; y el uso de los compuestos en el control de plagas de invertebrados en animales.
DOP2012000151A (es) Nuevos compuestos triciclicos
CL2010001483A1 (es) Compuestos derivados de 5-fenil-1h-piridin-2-ona y 6-fenil-2h-piridazin-3-ona, inhibidores de tirosina-quinasa (btk); composicion farmaceutica que comprende a dichos compuestos y su uso para el tratamiento de un estado patologico inflamatorio y/o autoinmune.
CR20110032A (es) Derivados de tiofeno y tiazol y su uso como inhibidores de p13k
CL2008000110A1 (es) Uso de compuestos derivados de piranona sustituidos para el tratamiento del sindrome metabolico; y compuestos derivados de piranona sustituidos.
CL2007003201A1 (es) Composicion farmaceutica liquida que comprende un derivado de ciclodextrina eterificada y un bencimidazol sustituido, donde el derivado de ciclodextrina se selecciona de eter de alfa, beta y gama-ciclodextrina; y uso para el tratamiento de insuficien
NL1036272A1 (nl) Radiation source, lithographic apparatus and device manufacturing method.
EA201290585A1 (ru) Труба солнечной панели
CL2009000532A1 (es) Compuestos derivados de piridin-2-ilo; agonista del receptor s1p1/edg1; composición farmacéutica que los comprende; uso en trastornos asociados con el sitema inmunitario.
AR064108A1 (es) Tratamiento de ansiedad con eszopiclona
CL2009001012A1 (es) Un metodo para el tratamiento de una condicion dependiente de progesterona que comprende el uso de una composicion que comprende una antiprogestina 19-noresteroide que contiene un anillo fenilo sustituido con monometilamina en la posicion 11 beta del carbono 11.
UY29774A1 (es) Inhibidor de atm
CL2008002705A1 (es) Composicion herbicida que comprende un compuesto con estructura piridazinona; metodo de control de malezas; uso del compuesto con estructura piridazinona para el control de malezas.
ITMI20061763A1 (it) Procedimento perfezionato di avvolgimento del filato in rocca con dispositivi guidafili individuali
CL2012001010A1 (es) Compuesto 4-[etil(dimetil)amonio]butanoato; procesos de preparacion de este compuesto; y su uso en el tratamiento de enfermedades cardiovasculares.
CL2009001089A1 (es) Compuestos derivados de indolo[2,1-a][2]benzacepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
CL2009000257A1 (es) Uso de imidazolinas 1,3 sustituidas y de sus sales fisiologicamente compatibles para el tratamiento del sindrome metabolico.
ECSP109874A (es) Nuevos compuestos 892
DE502008002979D1 (de) Arylsulfonamide mit analgetischer wirkung